Daniel E. Casey
#153,388
Most Influential Person Now
Daniel E. Casey's AcademicInfluence.com Rankings
Download Badge
Biology
Why Is Daniel E. Casey Influential?
(Suggest an Edit or Addition)Daniel E. Casey's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Physical health monitoring of patients with schizophrenia. (2004) (829)
- Antipsychotic-induced weight gain: a review of the literature. (2001) (637)
- Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. (2004) (386)
- Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate (2001) (251)
- Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study (2003) (249)
- The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. (1993) (232)
- Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia (2003) (227)
- Metabolic issues and cardiovascular disease in patients with psychiatric disorders. (2005) (211)
- Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. (1983) (193)
- Side effect profiles of new antipsychotic agents. (1996) (183)
- The relationship of pharmacology to side effects. (1997) (179)
- The pharmacology of weight gain with antipsychotics. (2001) (170)
- Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia (1991) (160)
- Pathophysiology of antipsychotic drug-induced movement disorders. (2004) (159)
- Tardive dyskinesia: pathophysiology and animal models. (2000) (159)
- The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity (1993) (136)
- Treatment of schizophrenia 1999 (1999) (136)
- Tardive dyskinesia and atypical antipsychotic drugs (1999) (117)
- Dose response of prophylactic antipsychotics. (1993) (117)
- Dyslipidemia and atypical antipsychotic drugs. (2004) (115)
- Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment (1989) (113)
- Antipsychotic drug-induced weight gain: development of an animal model (2005) (110)
- γ-Acetylenic GABA in Tardive Dyskinesia (1980) (101)
- Neuroleptic-induced parkinsonism in older schizophrenics (1987) (96)
- Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. (2004) (95)
- Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. (1993) (94)
- Motor and mental aspects of extrapyramidal syndromes (1995) (94)
- The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. (1991) (92)
- Clozapine: neuroleptic-induced EPS and tardive dyskinesia (2004) (89)
- Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. (1988) (88)
- Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. (2007) (73)
- Tardive dyskinesia in the aged. Duration of treatment relationships. (1985) (72)
- Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms (2006) (71)
- Dyskinesia. Research and treatment. (1985) (69)
- Metabolic effects of treatment with atypical antipsychotics. (2004) (69)
- A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. (2002) (68)
- Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia (2009) (68)
- Motor and mental aspects of acute extrapyramidal syndromes (1994) (66)
- Neuroleptic intolerance. (1997) (62)
- Experimental study of relation of fever to cerebral edema. (1974) (62)
- Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study (2008) (58)
- Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. (1991) (58)
- Neuroleptic intolerance : Clinical challenges in the psychopharmacology of schizophrenia (1997) (56)
- Ten-year outcome of tardive dyskinesia. (1994) (54)
- Pharmacology of blepharospasm‐oromandibular dystonia syndrome (1980) (54)
- Sulpiride in Tardive Dyskinesia (1984) (50)
- Tardive dyskinesia: reversible and irreversible. (1985) (49)
- Drug Evaluations: Drug Evaluation Central & Peripheral Nervous Systems: ‘Seroquel’ (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic (1996) (49)
- Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. (1998) (49)
- Tardive dyskinesia as a life-threatening illness. (1978) (47)
- Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. (1992) (44)
- Effect of gamma-vinyl GABA in tardive dyskinesia (1983) (43)
- Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. (1986) (43)
- Spontaneous and tardive dyskinesias: clinical and laboratory studies. (1985) (43)
- The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. (1982) (42)
- A Double-Blind Randomized Trial of Mood Stabilizer Augmentation Using Lamotrigine and Valproate for Patients With Schizophrenia Who Are Stabilized and Partially Responsive (2009) (41)
- Prediction of Neuroleptic‐Induced Dystonia (1987) (40)
- Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine (1986) (39)
- Three-year follow-up of older schizophrenics: Extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio (1991) (38)
- Deanol in the treatment of tardive dyskinesia. (1975) (38)
- Pharmacological characterization of tardive dyskinesia (1977) (36)
- Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates (1999) (35)
- Tardive dyskinesia--animal models. (1984) (34)
- Tardive dyskinesia and diabetes mellitus. (1992) (34)
- Dopamine, acetylcholine, and GABA effects in acute dystonia in primates (1980) (34)
- Psychopharmacology: Current Trends (1988) (31)
- Movements in never-medicated schizophrenics: a preliminary study (2005) (31)
- Letter: Dimethylaminoethanol in tardive dyskinesia. (1974) (31)
- Gamma-acetylenic GABA in tardive dyskinesia (1979) (31)
- Extrapyramidal Syndromes and New Antipsychotic Drugs: Findings in Patients and Non-human Primate Models (1996) (30)
- Acute Extrapyramidal Syndromes in Neuroleptic-Treated Elders: A Pilot Study (1991) (30)
- Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys (1990) (30)
- Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia (1981) (29)
- Behavioral aspects of GABA-dopamine interrelationships in the monkey (1979) (29)
- Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates (1993) (29)
- Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys (2005) (27)
- Effect of haloperidol and clozapine on the density of “perforated” synapses in caudate, nucleus accumbens, and medial prefrontal cortex (2005) (27)
- The differential diagnosis of tardive dyskinesia (1981) (24)
- Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. (1991) (24)
- Five-year follow-up study of tardive dyskinesia. (1985) (23)
- Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? (1997) (23)
- Computed tomographic evaluation of patients with tardive dyskinesia (1991) (22)
- Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates (2005) (22)
- Clinical management of acute neuroleptic-induced extrapyramidal syndromes. (1986) (21)
- Affective disorders and tardive dyskinesia. (1988) (21)
- Tardive dyskinesia in an adolescent. (1978) (21)
- Barriers to progress--the impact of tolerability problems. (2001) (21)
- Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. (1988) (20)
- Behavioral effects of sertindole, risperidone, clozapine and haloperidol inCebus monkeys (1996) (20)
- Coadministration of haloperidol and SCH-23390 prevents the increase in "perforated" synapses due to either drug alone. (1992) (19)
- Tardive dyskinesia: are there subtypes. (1976) (18)
- Extrapyramidal Syndromes (1996) (17)
- Predictors of engagement in first-episode psychosis (2016) (17)
- Amantadine intoxication reversed by physostigmine. (1978) (16)
- Tardive Dyskinesia: Management and New Treatment (1984) (16)
- Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment? (1983) (16)
- Drs. Casey and Rabins Reply (1978) (16)
- Neuroleptic‐potentiating effect of α‐methyl‐p‐tyrosine compared with haloperidol and placebo in a double‐blind cross‐over trial (1979) (15)
- Managing tardive dyskinesia. (1978) (15)
- Metoclopramide side effects. (1983) (15)
- Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia (2003) (15)
- Oxiperomide in tardive dyskinesia. (1980) (15)
- Behavioral effects of long-term neuroleptic treatment in Cebus monkeys. (1985) (14)
- Localized oral histoplasmosis. (1963) (14)
- Deanol in the management of involuntary movement disorders: a review. (1977) (13)
- A one-year comparison of four dosages of haloperidol decanoate (1993) (13)
- Sodium valproate in tardive dyskinesia. (1979) (12)
- Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse (2010) (12)
- Long-Term Treatment Goals: Enhancing Healthy Outcomes (2003) (11)
- Anticholinergic prophylaxis in young adults treated with neuroleptic drugs. (1986) (11)
- Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism (2004) (11)
- A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol (1998) (10)
- Neuropsychiatry of involuntary movement disorders. tardive dyskinesia (1991) (10)
- Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo. (1981) (10)
- Mood alterations during deanol therapy (1979) (9)
- Vasopressin in anergic schizophrenia (1981) (9)
- Effects of benztropine on ketamine‐induced behaviors in Cebus monkeys (2001) (9)
- Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response. (2012) (9)
- Striking a balance between safety and efficacy: experience with the SSRI sertraline (1994) (9)
- Clinical pharmacological approaches to evaluating tardive dyskinesia (1981) (9)
- Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy (2014) (8)
- International Clinical Psychopharmacology (2001) (8)
- D-1 and D-2 receptor manipulation in Cebus monkeys: implication for extrapyramidal syndromes in humans. (1986) (8)
- Tardive dyskinesia: Outcome at 10 years (1990) (8)
- S-69-3 Choreoathetoid movements occur spontaneously in never-medicated patients with schizophrenia (1996) (8)
- Atypical dysarthria in Munchausen syndrome. (1986) (7)
- Levodopa and receptor sensitivity modification in tardive dyskinesia (2004) (7)
- Dopaminergic and serotonergic aspects of acute extrapyramidal syndromes. (1993) (7)
- Sulpiride in tardive dyskinesia (1979) (6)
- Tardive dyskinesia status: stability or change. (1988) (6)
- Neuroleptic-induced parkinsonism increases with repeated treatment in monkeys. (1987) (6)
- Risk factors for drug-induced parkinsonism in tardive dyskinesia patients. (1988) (6)
- Enkephalin, morphine, and naloxone in tardive dyskinesia (1980) (6)
- Tardive dyskinesia: nondopaminergic treatment approaches. (1985) (6)
- Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia (2003) (6)
- Dopamine antagonist and agonist treatment of tardive dyskinesia. (1980) (5)
- The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates (2001) (5)
- Atypical antipsychotics: enhancing healthy outcomes. (2002) (5)
- Choosing among old and new antipsychotics. (1996) (5)
- Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys (1987) (4)
- Unexpected intracerebral pathology in older schizophrenic patients. (1991) (4)
- Serotonin and dopamine relationships in nonhuman primate extrapyramidal syndromes (1991) (4)
- Tardive dyskinesia: epidemiologic factors as a guide for prevention and management. (1985) (4)
- High-dose destyrosine-γ-endorphin in tardive dyskinesia (2004) (4)
- Effect of apomorphine and Gabaergic drugs in monkeys pretreated with haloperidol (1983) (4)
- Letter: Deanol for tardive dyskinesia. (1975) (4)
- Comparative Studies of Abnormal Involuntary Movements in Never-treated Vs Treated Populations with Schizophrenia (1996) (4)
- Clinical trial design issues in schizophrenic research. (2001) (4)
- Neuroleptic-Induced Movement Disorders: Tardive dyskinesia and affective disorder (1984) (3)
- The effect of γ-vinyl GABA on amphetamine stereotypy in rats (1980) (3)
- A longitudinal study of correlations among tardive dyskinesia, drug-induced parkinsonism, and psychosis. (1992) (3)
- DU 127090: A highly potent, atypical dopamine receptor ligand — Behavioral effects of DU 127090 in Cebus non-human primates (2000) (3)
- The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys (1995) (3)
- Introduction. Antipsychotic standard of care: Redefining the definition of atypical antipsychotics (2000) (3)
- A multicenter double-blind comparative trial of raclopride versus haloperidol in schizophrenia (1991) (3)
- Treatment of fractures of the maxilla and mandible. (1968) (2)
- AFFECTIVE CHANGES WITH DEANOL (1979) (2)
- Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia. (1981) (2)
- Reply: Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia (2004) (2)
- Deanol Trials in Tardive Dyskinesia (1979) (2)
- Dopamine agonists in clinical research for new tardive dyskinesia treatments. (1983) (2)
- gamma-Acetylenic GABA in tardive dyskinesia. (1980) (2)
- Sulpiride and oxiperomide in tardive dyskinesia. (1979) (2)
- Neuroleptic-potentiating effect of metyrosine. (1979) (2)
- Longitudinal assessment of older schizophrenic patients. (1989) (2)
- Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeys. (2003) (2)
- Schizophrenia, Metabolic Disorders, and Cardiovascular Disease (2004) (2)
- Tardive dyskinesia and dopaminergic hypersensitivity: Long term neuroleptic treatment in cebus monkeys (1989) (2)
- A novel dopamine D1 antagonist can prevent sensitization to abnormal movements by haloperidol (1993) (2)
- Mild tardive dystonia is common in chronic schizophrenics (1995) (1)
- The role of dopamine receptor subtypes in nonhuman primate models of antipsychotic drug-induced movement disorders (1995) (1)
- Bipolar disorder: Diagnostic challenges and treatment strategies (2006) (1)
- P-13-8 A fifteen year follow-up study of tardive dyskinesia and drug induced Parkinsonism (1996) (1)
- Simultaneous metastatic epidermoid carcinoma and chronic granulocytic leukemia. (1978) (1)
- Tardive dyskinesia: resolving, persisting, new cases—demographics and treatment (1989) (1)
- DU127090: A novel partial dopamine agonist with antipsychotic activity behavioral effects of DU127090 in cebus non-human primates (2003) (1)
- Introduction: Update on Tardive Dyskinesia (2000) (1)
- Duration of Treatment Relationships for Involuntary Movements (Tardive Dyskinesia): Concordance Between Cross-sectional, Clinical, and Longitudinal Animal Studies?-Reply (1986) (1)
- Actual versus self-reported intake and exercise in obesity. (1993) (1)
- S-12-5 Atypical neuroleptics in older monkeys (1996) (1)
- Elderly psychiatric patients: Parkinsonism, sex, and MAO relationships (1989) (1)
- S-2-2 Movement disorders in schizophrenia: Current considerations (1995) (0)
- High-dose destyrosine-gamma-endorphin in tardive dyskinesia. (1982) (0)
- Longitudinal evaluation of older schizophrenics (1989) (0)
- Concluding remarks (1995) (0)
- Acute extrapyramidal syndromes: Clinical characteristics implicate different pathophysiologies (1991) (0)
- Development and characterization of anti-spiroperidol antibodies. (1988) (0)
- Optimizing Treatment for Patients With Schizophrenia: Targeting Positive Outcomes (2003) (0)
- SHORT‐TERM NEUROLEPTIC WITHDRAWAL IN SCHIZOPHRENIA (1992) (0)
- Reply from Drs Keeper and Casey (1989) (0)
- Significant interactions: Gender, movement disorders, and biochemical variables (1995) (0)
- Negative symptoms of schizophrenia: Relationship to drug-induced parkinsonism (1993) (0)
- Specific characteristics of EPS — implications for drug development (1999) (0)
- Comparison methods of quantification of spect brain images in psychiatric research (1991) (0)
- Neuroleptic-induced extrapyramidal syndrome liability and dopamine/serotonin antagonism (1989) (0)
- Serum haloperidol and anticholinergic levels in drug-induced parkinsonism (1989) (0)
- Dopaminergic and GABAergic aspects of tardive dyskinesia [proceedings]. (1981) (0)
- Enkephalin, Naloxone, and [Des-Tyr1]-γ-Endorphin in Tardive Dyskinesia (1982) (0)
- Drs. Casey and Denney Reply (1976) (0)
- Effect of adjunctive aripiprazole in achieving various levels of response and on domains of functioning in MDD: A pooled analysis (2011) (0)
- Healthy outcomes in schizophrenia - Introduction (2001) (0)
- Dystonia and haloperidol pharmacokinetics (1989) (0)
- TARDIVE DYSKINESIA MECHANISMS AND ABNORMAL GLUCOSE METABOLISM (1994) (0)
- New antipsychotics: preclinical and clinical research (1996) (0)
- DEANOLTRIALS IN TARDIVE DYSKINESIA (1979) (0)
- LATERALITY OF ACUTE AND TARDIVE EXTRAPYRAMIDAL SYNDROMES (1992) (0)
- Dopaminergic behavioral hypersensitivity in monkeys receiving long term neuroleptic treatment (1990) (0)
- Contents of the American Journal of Psychiatry (2004) (0)
- Behavioral aspects of GABA-dopamine interrelationships in the monkey (1979) (0)
- The effect of raising brain GABA on an animal model of hyperkinesia (1980) (0)
- EPS PROFILE OF ANTIPSYCHOTICS : ANIMAL AND HUMAN EXPERIENCE (1998) (0)
- Brief neuroleptic treatment causes lasting changes in extrapyramidal syndromes and sedation in monkeys (1989) (0)
- The Impact of Atypical Antipsychotics on Weight Gain (2004) (0)
- Drug treatment of schizophrenia: From molecular biology to patients' subjective experience: Concluding remarks (1995) (0)
- Effect of neuroleptic withdrawal on the relationship of tardive dyskinesia and ventricular enlargement (1991) (0)
- The effect of dopamine agonists in monkeys as a function of haloperidol treatment (1982) (0)
- Epidemiology of Cardiovascular Disease and Major Metabolic Risk Factors (2004) (0)
- Dopaminergic and serotonergic effects on spontaneous orofacial dyskinesias in cebus monkeys. (1996) (0)
- Cognition in drug-induced and idiopathic parkinsonism (1989) (0)
- Acute neuroleptic drug-induced extrapyramidal syndromes: Current concepts and controversies (1989) (0)
- SEROTONERGIC AND CHOLINERGIC ANTAGONISTS IN PREVENTING OR TREATING HALOPERIDOL‐INDUCED DYSTONIA IN MONKEYS (1992) (0)
- Lack of platelet monoamine oxidase activity in Cebus monkeys (Cebus albifrons). (1989) (0)
- Timing of neuroleptic-induced dystonia and dystonia pathophysiology (1989) (0)
- Rapid semi-automated CT determination of ventricular area (1989) (0)
- Prevalence and time course of neuroleptic-induced akathisia (1992) (0)
- The effect of atypical antipsychotic drugs in patients with preexisting diabetes (2003) (0)
- International Clinical Psychopharmacology: Introduction (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Daniel E. Casey?
Daniel E. Casey is affiliated with the following schools:
